← Back to Search

Behavioral Intervention

Telehealth MCBT for Chronic Pain & Problem Drinking in HIV/AIDS

N/A
Recruiting
Led By Tibor P Palfai, PhD
Research Sponsored by Boston University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Summary

This trial compares a remote Motivational & Cognitive Behavioral Intervention to a Brief Advice & Information Control to help HIV patients manage their alcohol use & chronic pain.

Who is the study for?
This trial is for adults in the USA with HIV/AIDS who have chronic pain (4+ on the pain scale) for at least 3 months and engage in unhealthy drinking. They must own a smartphone, confirm their HIV status via Zoom, and not be receiving current treatment for alcohol or pain issues. People with bipolar disorder, schizoaffective disorder, schizophrenia, unstable medication doses, history of severe withdrawal symptoms from alcohol, cancer-related pain or life-threatening illnesses are excluded.
What is being tested?
The study compares two approaches: MCBMAP (a motivational and cognitive behavioral management program) versus brief advice and information control condition to manage chronic pain and problem drinking among people living with HIV. Participants will use videoconferencing for sessions after an initial remote assessment phase including ecological momentary assessments over two weeks.
What are the potential side effects?
Since this trial involves behavioral interventions rather than medications or medical procedures, traditional side effects are not expected. However, participants may experience discomfort discussing personal habits like drinking or dealing with emotional responses during therapy.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of alcoholic drinks consumed per week at 6 months
Number of heavy episodic drinking days the past month at 6 months
Rating of pain severity and interference at 6 months
Secondary study objectives
Rating of pain interference at 6 months
Rating of pain severity at 6 months

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Motivational and Cognitive-Behavioral Management for Alcohol and Pain Intervention (MCBMAP)Experimental Treatment1 Intervention
Participants randomized to this arm will receive MCBMAP which utilizes a self-regulation framework to integrate evidence-based approaches for chronic pain and unhealthy drinking.
Group II: Brief Advice and InformationActive Control1 Intervention
Participants randomized to this arm will be provided treatment as usual for their conditions.

Find a Location

Who is running the clinical trial?

Boston UniversityLead Sponsor
467 Previous Clinical Trials
9,953,883 Total Patients Enrolled
4 Trials studying Chronic Pain
276 Patients Enrolled for Chronic Pain
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
823 Previous Clinical Trials
1,160,921 Total Patients Enrolled
9 Trials studying Chronic Pain
599 Patients Enrolled for Chronic Pain
Tibor P Palfai, PhDPrincipal InvestigatorBoston Medical Center, Psychiatry; BU Psychological & Brain Sciences
1 Previous Clinical Trials
8 Total Patients Enrolled
1 Trials studying Chronic Pain
8 Patients Enrolled for Chronic Pain

Media Library

MCBMAP (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05503173 — N/A
Chronic Pain Research Study Groups: Brief Advice and Information, Motivational and Cognitive-Behavioral Management for Alcohol and Pain Intervention (MCBMAP)
Chronic Pain Clinical Trial 2023: MCBMAP Highlights & Side Effects. Trial Name: NCT05503173 — N/A
MCBMAP (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05503173 — N/A
~181 spots leftby Feb 2026